Episode Details

In his weekly clinical update, Dr. Griffin discusses expanded use of the RSV vaccine by GSK, how the youngest member of the MicrobeTV family was hospitalized with RSV, why we are seeing more RSV infections than before the pandemic and how administration of monoclonal antibody therapy does not prevent infection but disease, before reviewing the weekly US COVID update, how SARS-CoV-2 affects neurodevelopment of the fetus and probability of preeclampsia, if giving Paxlovid prevents long COVID, and FDA recommends switching from the XBB.1.5 variant to JN.1 for fall COVID-19 vaccine formulations.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Young “Immune” co-host with RSV (YouTube)
• RSV on Immune (MicrobeTV)
• More children hospitalized with RSV after pandemic than before (Pediatrics)
• France supports Nirsevimab for RSV (Influenza and other respiratory viruses)
• Protects against disease not infection Nirsevimab (CIDRAP)
• TWiV tells it likes it is: protects against disease NOT infection (TWiV 695)
• RSV vaccine access expanded 50-59 (CIDRAP)
• GSK RSV vaccine expanded use for high risk 50-year olds (GSK)
• COVID-19 deaths
• COVID-19 national trend
• Neurodevelopmental delay in children whose mothers exposed to SARS-CoV-2 (Scientific Reports)
• Preeclampsia associated with SARS-CoV-2 infection (Journal of Maternal-Fetal & Neonatal Medicine)
• Effectiveness of nirmatelvir/ritonavir in children and adolescents (Nat Comm)
• JN.1 for fall COVID-19 boosters (FDA)
• COVID-19 vaccine booster switch (CIDRAP)
• EUA for pemgarda (FDA)
• Infusion centers near you! (pemgarda.com)
• CDC quarantine guidelines (CDC)